血红蛋白疾病治疗的全球市场 - 市场规模、份额、成长分析：按治疗方法、按应用分类 - 产业预测（2023-2030）

Global Hemoglobinopathies Treatment Market Size, Share, Growth Analysis, By Treatment(Stem cell therapy, blood transfusion), By Application(Thalassemia, sick cell anaemia and others) - Industry Forecast 2023-2030

出版日期: 2023年10月08日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2021年全球血红素病治疗市场规模为76.3亿美元，2022年为83.2亿美元。预计该市场在预测期（2023-2030年）将以9%的年复合成长率成长，到2030年将达到165.7亿美元。

全球血红蛋白疾病治疗市场是一个快速成长的领域，涵盖用于管理和治疗镰状细胞疾病（SCD）和地中海贫血等血红蛋白疾病的多种治疗方法和解决方案。血红蛋白病是一组遗传性血液疾病，其特征是血红蛋白的结构和产生异常，导致各种併发症和症状。市场在治疗选择方面取得了重大进展，包括基因疗法、干细胞移植和新型药物疗法。这些创新治疗方法有可能解决潜在的遗传缺陷、减轻症状并改善患者的生活品质。新兴市场的研发活动、研究合作和策略联盟也激增，以加速开发并将新治疗方法推向市场。此外，新兴国家对这些疾病的认识不断提高、政府支持措施以及医疗基础设施的改善正在推动市场成长。然而，治疗费用高昂、某些地区获得先进治疗手段有限以及需要专业医疗人员等挑战是市场扩张的障碍。总体而言，持续的研究、技术进步以及对个人化医疗方法的日益关注，以满足血红蛋白疾病患者未满足的需求，正在推动全球市场的显着成长。

全球血红蛋白疾病治疗市场的主要驱动力之一是对个人化医疗方法的日益关注。个人化医疗旨在根据患者个别特征（例如遗传倾向、疾病严重程度和治疗反应）制定治疗策略。基因检测和分子诊断的进步使医疗保健提供者能够更好地了解血红蛋白疾病背后的特定基因突变和异常。这些知识有助于开发标靶治疗和精准医学介入措施，从而改善治疗结果和患者满意度。强调个人化医疗不仅会提高治疗血红素病的有效性，还会促进创新治疗方案的发展。

全球血红蛋白病治疗市场的主要抑制因素是先进治疗方法的高成本。许多新治疗方法，例如基因疗法和干细胞移植，都涉及复杂的程序、专门的设备和广泛的后续护理。这些因素导致与这些治疗相关的高成本，对患者和医疗保健系统造成经济负担。特别是在医疗资源有限和低收入人口众多的地区，先进治疗方法的可负担性和可近性是一个问题。高昂的治疗费用可能会限制新治疗方法的普及，阻碍患者获得治疗，并导致血红蛋白病患者的医疗结果有差异。解决成本障碍对于确保所有患者都能公平地获得有效治疗至关重要。

该报告研究了全球血红蛋白疾病治疗市场，并提供了市场概述，包括治疗方法、应用、地区和参与市场的公司概况分類的趋势。

主要企业简介
- Sanofi SA
- Global Blood Therapeutics, Inc.
- bluebird bio, Inc
- EMI Holding, Inc
- Celgene Corporation
- Novartis AG
- Gilead Sciences, Inc.
- CRISPR Therapeutics AG
- Sangamo Therapeutics, Inc.
- Vertex Pharmaceuticals Incorporated
- Pfizer Inc.
- Bioverativ Inc.
- Acceleron Pharma Inc.
- Agios Pharmaceuticals, Inc
- Gamida Cell Ltd.
- Orchard Therapeutics plc
- Emmaus Life Sciences, Inc.
- Pharmacosmos A/S
- Fresenius SE &Co. KGaA
- Bluebird R&D Spain SLU

简介目录

Product Code: SQMIG35H2110

Global Hemoglobinopathies Treatment Market size was valued at USD 7.63 billion in 2021 and is poised to grow from USD 8.32 billion in 2022 to USD 16.57 billion by 2030, at a CAGR of 9% during the forecast period (2023-2030).

The global hemoglobinopathies treatment market is a rapidly growing sector that encompasses a wide range of therapeutic approaches and solutions aimed at managing and treating hemoglobinopathies, including sickle cell disease (SCD) and thalassemia. Hemoglobinopathies are a group of inherited blood disorders characterized by abnormalities in the structure or production of hemoglobin, leading to various complications and symptoms. The market is witnessing significant advancements in treatment options, including gene therapy, stem cell transplantation, and novel drug therapies. These innovative treatments offer the potential to address the underlying genetic defects, alleviate symptoms, and improve the quality of life for patients. The market is also experiencing a surge in research and development activities, collaborations, and strategic partnerships to accelerate the development of novel therapies and bring them to the market. Additionally, increasing awareness about these disorders, supportive government initiatives, and improved healthcare infrastructure in emerging economies are driving market growth. However, challenges such as high treatment costs, limited accessibility to advanced therapies in certain regions, and the need for specialized healthcare professionals pose obstacles to market expansion. Overall, the global market is poised for substantial growth, driven by ongoing research, technological advancements, and a growing emphasis on personalized medicine approaches to address the unmet needs of patients with hemoglobinopathies.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Emergency Lighting Systems Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemoglobinopathies Treatment Market Segmental Analysis

Global Hemoglobinopathies Treatment Market is segmented on the basis of treatment, application and region. By treatment, the market is segmented into Stem cell therapy, blood transfusion, iron chelation therapy and others. By application, the market is segmented into Thalassemia, sick cell anaemia and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Hemoglobinopathies Treatment Market Dynamics

Drivers of the Global Hemoglobinopathies Treatment Market

Increasing focus on personalized medicine approaches

One key driver of the global hemoglobinopathies treatment market is the increasing focus on personalized medicine approaches. Personalized medicine aims to tailor treatment strategies based on individual patient characteristics, including their genetic makeup, disease severity, and response to therapy. With advancements in genetic testing and molecular diagnostics, healthcare providers are able to better understand the specific genetic mutations and abnormalities underlying hemoglobinopathies. This knowledge enables the development of targeted therapies and precision medicine interventions that can improve treatment outcomes and patient satisfaction. The emphasis on personalized medicine not only enhances the effectiveness of hemoglobinopathies treatment but also promotes the development of innovative therapeutic options.

Restraints in the Global Hemoglobinopathies Treatment Market

High cost of advanced therapies

A key restraint of the global hemoglobinopathies treatment market is the high cost of advanced therapies. Many of the emerging treatment modalities, such as gene therapy and stem cell transplantation, involve complex procedures, specialized equipment, and extensive follow-up care. These factors contribute to the high cost associated with these treatments, making them financially burdensome for patients and healthcare systems. The affordability and accessibility of advanced therapies pose challenges, particularly in regions with limited healthcare resources and lower income populations. The high cost of treatment limits the widespread adoption of novel therapies, potentially hindering patient access and leading to disparities in healthcare outcomes for individuals with hemoglobinopathies. Addressing the cost barrier is crucial to ensure equitable access to effective treatments for all patients

Global Hemoglobinopathies Treatment Key Market Trends

Growing emphasis on gene therapy

One key market trend in the global hemoglobinopathies treatment market is the growing emphasis on gene therapy. Gene therapy has emerged as a promising approach for the treatment of hemoglobinopathies, including sickle cell disease and thalassemia. The advancements in genetic engineering techniques, such as CRISPR/Cas9, have provided new possibilities for correcting the genetic mutations underlying these disorders. Gene therapy offers the potential to address the root cause of hemoglobinopathies by introducing functional genes or modifying the existing genes to restore normal hemoglobin production. The increasing research and development activities in gene therapy, along with the successful clinical trials and regulatory approvals, highlight the significant market trend towards this innovative treatment modality.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
- Regulatory Landscape
- Porters Analysis
Competitive rivalry
Threat of Substitute Products
Bargaining Power of Buyers
Threat of New Entrants
Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
Political Impact
Economic Impact
Social Impact
Technical Impact
Environmental Impact
Legal Impact
Global Hemoglobinopathies Treatment Market by Treatment
- Market Overview
- Stem cell therapy
- blood transfusion
- iron chelation therapy and others
Global Hemoglobinopathies Treatment Market by Application
- Market Overview
- Thalassemia
- sick cell anaemia and others
Global Hemoglobinopathies Treatment Market Size by Region
- Market Overview
- North America
USA
Canada
- Europe
Germany
Spain
France
UK
Rest of Europe
- Asia Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
- Latin America
Brazil
Rest of Latin America
- Middle East & Africa (MEA)
GCC Countries
South Africa
Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
By Development
By Company
By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Sanofi S.A. (France)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Global Blood Therapeutics, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- bluebird bio, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- EMI Holding, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Celgene Corporation (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Novartis AG (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Gilead Sciences, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- CRISPR Therapeutics AG (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Sangamo Therapeutics, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Vertex Pharmaceuticals Incorporated (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Pfizer Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Bioverativ Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Acceleron Pharma Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Agios Pharmaceuticals, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Gamida Cell Ltd. (Israel)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Orchard Therapeutics plc (UK)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Emmaus Life Sciences, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Pharmacosmos A/S (Denmark)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Fresenius SE & Co. KGaA (Germany)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Bluebird R&D Spain SLU (Spain)
Company Overview
Business Segment Overview
Financial Updates
Key Developments